CURRICULUM VITAE

Professor Hans Schöler

Dr. rer. nat.

Max Planck Institute for Molecular Biomedicine

http://www.mpi-muenster.mpg.de

Academic Appointments:	
1984-1986	Staff Scientist, Center for Molecular Biology Heidelberg (ZMBH), University of
	Heidelberg, Germany
1986-1988	Head Research Group, Boehringer Mannheim Research Center, Tutzing, Germany
1988-1991	Staff Scientist, Max Planck Institute for Biophysical Chemistry, Göttingen,
	Germany
1991-1999	Head Research Group, European Molecular Biology Laboratory (EMBL),
	Heidelberg, Germany
1999-2004	Professor of Reproductive Physiology, School of Veterinary Medicine, and Director
	of the Center for Animal Transgenesis and Germ Cell Research at the University of
	Pennsylvania, Philadelphia, USA
2000-2004	The Marion Dilley and David George Jones Chair in Reproduction Medicine

Scientific and Academic Curriculum:

1999-2004	Professor and Chair in Reproduction Medicine at the University of Pennsylvania, School of Veterinary Medicine, Department of Animal Biology in Philadelphia, USA (since 2004: Adjunct Professor)
Since 2004	Director at the Max Planck Institute for Molecular Biomedicine, Department for
	Cell and Developmental Biology, Münster, Germany
Since 2004	Professor at the Medical Faculty of the Westphalian Wilhelms-University Münster,
	Münster, Germany
Since 2009	Adjunct Professor at the "Medizinische Hochschule Hannover" (MHH), Hanover,
	Germany
Since 2012	Adjunct Professor at the UNIST, Ulsan, South Korea

Scientific Awards and Honors:

2004	Member of the German National Academy of Sciences Leopoldina
2005	Head of the Managing Board of the Stem Cell Network North Rhine-Westphalia
2005	Member of the North Rhine-Westphalian Academy of Sciences, Humanities and
	the Arts
2008	Robert Koch Prize
2010	Corresponding Member of the Berlin-Brandenburg Academy of Sciences and
	Humanities
2010	Corresponding Member of the Academy of Sciences and Literature Mainz

Research Interests:

Molecular biology of the mammalian germline (pluripotent cells and germ cells), in vitro and in vivo reprogramming; disease modelling and drug screening